Arvinas will share Q2 2025 financial results and updates via a webcast on August 6, 2025.
Quiver AI Summary
Arvinas, Inc., a clinical-stage biotechnology company specializing in targeted protein degradation, announced a live webcast on August 6, 2025, at 8:00 a.m. ET to review its financial results for the second quarter of 2025 and provide a corporate update. The webcast will be accessible via the investor page on their website, with a replay available afterward. Arvinas utilizes its PROTAC technology to develop therapies aimed at degrading harmful proteins, with several investigational drugs in clinical programs targeting various cancers and neurodegenerative disorders. The company is based in New Haven, Connecticut.
Potential Positives
- Arvinas, Inc. is set to provide a corporate update and financial results for Q2 2025, indicating transparency and engagement with investors.
- The company is advancing multiple investigational drugs through clinical development, showcasing a strong pipeline in targeted protein degradation therapies.
- The focus on innovative treatments for serious conditions such as cancer and neurodegenerative disorders underscores Arvinas' commitment to addressing significant health challenges and improving patient outcomes.
Potential Negatives
- The press release does not include any specific financial results or details about the company's performance, which may indicate a lack of positive developments or transparency about their current financial health.
- There is no mention of any recent successes or advancements in the clinical development programs, which could raise concerns about the progress of their investigational drugs.
- The reliance on a live webcast for corporate updates may signal a lack of proactive communication, leaving investors and stakeholders without immediate access to critical information.
FAQ
When is Arvinas' next financial results webcast?
Arvinas' next financial results webcast is scheduled for Wednesday, August 6, 2025, at 8:00 a.m. ET.
How can I access the Arvinas webcast?
The webcast can be accessed under “Events and Presentations” on the investor page of Arvinas' website.
What is the focus of Arvinas' drug development?
Arvinas focuses on developing therapies based on targeted protein degradation to treat debilitating and life-threatening diseases.
What investigational drugs is Arvinas currently developing?
Arvinas is developing multiple drugs, including vepdegestrant, ARV-393, ARV-102, and ARV-806 for various cancers and neurodegenerative disorders.
Where is Arvinas located?
Arvinas is headquartered in New Haven, Connecticut.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- JOHN G HOUSTON (President and CEO) has made 0 purchases and 2 sales selling 31,338 shares for an estimated $523,880.
- IAN TAYLOR (President, R&D) has made 0 purchases and 2 sales selling 9,020 shares for an estimated $150,752.
- ANGELA M CACACE (Chief Scientific Officer) has made 0 purchases and 3 sales selling 6,790 shares for an estimated $89,584.
- NOAH BERKOWITZ (Chief Medical Officer) sold 8,658 shares for an estimated $74,372
- ANDREW SAIK (Chief Financial Officer) sold 5,700 shares for an estimated $43,377
- DAVID K LOOMIS (Chief Accounting Officer) sold 1,214 shares for an estimated $20,334
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 122 institutional investors add shares of $ARVN stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC removed 6,726,491 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $47,219,966
- BELLEVUE GROUP AG removed 2,389,600 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $16,774,991
- ALYESKA INVESTMENT GROUP, L.P. added 1,800,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,636,000
- ARROWMARK COLORADO HOLDINGS LLC removed 1,776,555 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,471,416
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,660,130 shares (-75.2%) from their portfolio in Q1 2025, for an estimated $11,654,112
- UBS GROUP AG removed 1,563,150 shares (-76.7%) from their portfolio in Q1 2025, for an estimated $10,973,313
- JPMORGAN CHASE & CO removed 1,484,609 shares (-79.9%) from their portfolio in Q1 2025, for an estimated $10,421,955
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/15/2025
- BMO Capital issued a "Outperform" rating on 05/05/2025
- Wells Fargo issued a "Overweight" rating on 05/02/2025
- Guggenheim issued a "Buy" rating on 05/02/2025
- Piper Sandler issued a "Overweight" rating on 05/02/2025
- Barclays issued a "Overweight" rating on 05/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 19 analysts offer price targets for $ARVN in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Andrew Berens from Leerink Partners set a target price of $9.0 on 06/02/2025
- Eliana Merle from UBS set a target price of $21.0 on 05/15/2025
- Terence Flynn from Morgan Stanley set a target price of $11.0 on 05/09/2025
- Yigal Nochomovitz from Citigroup set a target price of $9.5 on 05/05/2025
- Srikripa Devarakonda from Truist Securities set a target price of $11.0 on 05/05/2025
- Evan David Seigerman from BMO Capital set a target price of $10.0 on 05/05/2025
- Derek Archila from Wells Fargo set a target price of $19.0 on 05/02/2025
Full Release
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
